

Integrating QMS and Cyber Security

#### Track 5

Jens Lauber

Global Lead Quality & Regulatory Services, Medical Devices, Accenture

### Introduction to the EU AI Act

### Top 6 keywords you need to know about the EU AI Act

The **EU AI Act** is the first comprehensive legal framework designed to regulate artificial intelligence across Europe. Its primary goal is to ensure that AI is used safely, ethically, and transparently, while fostering innovation. The Act categorizes AI systems based on their risk level and sets requirements for their deployment, with a strong emphasis on **accountability**, **transparency**, and **human oversight**. Understanding its provisions is essential for companies to ensure compliance and unlock AI's full potential responsibly.

### Legislation



- The EU AI Act is a piece of legislation by the EU – it is legally binding.
- It regulates the development and use of AI systems.

#### Horizontal



- The EU AI Act is horizontal, meaning it is not industryspecific.
- It covers all industries and use cases.

### Risk-based



- The EU AI Act adopts a risk-based approach and classifies AI systems based on the risks they pose.
- The higher the risk, the more stringent the requirements and obligations are.

#### Extraterritorial



- The EU Al Act is extraterritorial.
- It does not only regulate EU companies, but also Al systems developed outside of EU that are placed on the EU market, or if the system outputs are being used within the EU.

### Provider vs Deployer



- Al systems are developed and distributed through complex value chains.
- The Act differentiates between providers (i.e. developers) and deployers (i.e. users).

# Staggered Implementation



- The EU AI Act has come into force in Aug 2024.
- There is a staggered implementation, starting at the 6month mark.



## **EU AI Act**

## Shaping the Future of AI Regulation

	Examples	Requirements	
		Providers	Deployers
Prohibited Al Systems	<ul> <li>Predictive Policing</li> <li>Social Scoring</li> <li>Untargeted scraping of facial images</li> <li>Emotion recognition in workplace</li> </ul>	Completely banned in EU	
High-risk Al Systems	<ul> <li>Al enabled Medical Devices</li> <li>Biometric identification (except for self-identification)</li> <li>Human resources management (e.g. CV screening, systems used for promotion / termination decisions)</li> <li>Credit scoring</li> <li>Insurance pricing and risk assessment</li> <li>Law enforcement, migration and border control</li> <li>Critical infrastructure</li> <li>Al systems used as safety component of products governed by EU law</li> </ul>	<ul> <li>Risk management</li> <li>Data governance</li> <li>Technical doc</li> <li>Record-keeping</li> <li>Instructions of use</li> <li>Human oversight</li> <li>Accuracy, robustness and cybersecurity</li> <li>Conformity assessment</li> <li>Monitoring &amp; incident reporting</li> <li>EU database registration</li> </ul>	<ul> <li>Use Al system according to instructions</li> <li>Human oversight</li> <li>Fundamental rights impact assessment</li> <li>Monitoring &amp; incident reporting</li> </ul>
Limited Risk Al Systems	<ul> <li>Al chatbots and Al-powered search engines</li> <li>Al-based recommendation systems (e.g. movie or shopping recommendations)</li> <li>Al-generated content (e.g. Al-written news)</li> </ul>	<ul> <li>Transparency obligations</li> <li>Prevent manipulation or deception</li> <li>Ensure data protection and security</li> </ul>	<ul> <li>Ensure Al-generated content is labelled</li> <li>Provide human oversight where needed</li> </ul>
Minimal Risk Al Systems	<ul> <li>Al-driven spelling and grammar checkers</li> <li>Al-powered spam filters and email categorization</li> <li>Automated data entry tools</li> </ul>	No mandatory	legal obligations

# **QMS Obligations in EU AI Act**

Providers of high-risk AI systems are required to put in place a Quality Management System (QMS), which includes a number of aspects that are mapped to a Responsible AI (RAI) capability framework



# **Impact on Life Science Companies**

### From Guidelines to Practice

The **EU AI Act** establishes **clear regulations** for AI systems in **life sciences**, ensuring **safety**, **accountability**, **and ethical AI deployment**. Companies must transition from **compliance guidelines** to **practical implementation** by addressing key challenges in AI governance, risk management, and regulatory adherence.

Challenge

**Impact on Life Science Companies** 

**Solution** 

**AI Risk Classification** 

Companies must assess AI systems based on potential risks to patient safety, clinical outcomes, and regulatory compliance.

**Establish** clear **AI risk categorization frameworks** early in the process to ensure compliance with EU regulations and prioritize resources for high-risk AI systems.

Transparency & Explainability

Al models must be interpretable, especially in drug discovery, clinical trials and clinical decision support systems. Black-box models face regulatory hurdles.

Integrate explainable AI (XAI) methodologies to ensure clarity in AI decision-making, making it easier for stakeholders to trust and regulatory bodies to approve.

Data Integrity & Bias Mitigation

Al systems must ensure fairness and prevent biases in clinical data. Biased Al can lead to unsafe treatments and unreliable outcomes.

Develop **robust data governance frameworks** to monitor and eliminate biases in datasets, ensuring AI systems provide equitable and accurate results across all demographics.

Monitoring & Reporting

Continuous evaluation of AI systems in clinical trials, drug development, and routine use is necessary to maintain compliance and ensure patient safety.

**Implement real-time monitoring** systems that can flag issues and ensure regulatory bodies are informed of any deviations or risks in a timely manner.



High-risk AI systems need **detailed documentation** to meet regulatory requirements.

Utilize automated **compliance tools to track and manage Al documentation**, helping companies stay compliant and streamline their regulatory submission processes.





# **Cyber Resilience Act (CRA)**

The EU's Cyber Resilience Act is a regulation to strengthen cybersecurity requirements for products with digital elements (PDEs), including both hardware and software — AI systems included.

In-scope: Software or hardware product and its remote data processing solutions, known as "products with digital elements", that are logically or physically connected to a device or network

Out of scope:

- Medical devices, in vitro diagnostic medical devices (regulated by EU MDR / IVDR, motor vehicles, civil aviation, marine equipment (all considered high-risk under EU AI Act)
- National security or defence

=> Indirect impact on healthcare industry

	Default Category	Important Products (Annex III)		Critical Products
		Class I	Class II	(Annex IV)
Examples	All products with digital elements without a classification, e.g.:  • Simple IoT devices  • Photo-editing software	<ul> <li>Identity management</li> <li>Password managers</li> <li>Routers or modems</li> <li>Personal wearable products</li> </ul>	<ul> <li>Hypervisors</li> <li>Firewalls</li> <li>Intrusion detection</li> <li>Tamper-resistant microprocessors</li> </ul>	<ul><li>Hardware devices with security boxes</li><li>Smart meter gateways</li><li>Smartcards</li></ul>
Manufacturer Obligations (non-exhaustive)	Cybersecurity (Annex I):  Vulnerability handling (Annex I):  Other obligations (Article 13):  Identify, document, address & remediate vulnerabilities  Protect from unauthorised access  Protect data confidentiality and integrity, data minimisation  Reduce incident impact  Reduce incident impact  Allow permanent setting removal  Vulnerability handling (Annex I):  Identify, document, address & remediate vulnerabilities  Instructions to user (Annex II)  Technical documentation (Annex VII)  CE marking, declaration of conformity  Include type, batch or serial no.  Designate single point of contact			
Conformity Assessment	Self-assessment	Self-assessment if harmonised standards are available and adopted  Third-party conformity assessment if otherwise	Third-party conformity assessment	European cybersecurity certifications scheme

# Confidentiality & Security

Privacy and confidentiality could be compromised by output data revealing sensitive patient data or proprietary research information. Breaches and adversarial attacks can lead to unauthorized access, damaging patient trust and exposing the organisation to legal and reputational risks.

## **CRA and EU AI Act Interlock**

Article 12 of CRA defines the interlock with EU AI Act, in particular how compliance with the CRA cybersecurity requirements would provide presumption of conformity for the cybersecurity requirements in Article 15 of the EU AI Act.

	CRA	EU AI Act	
Scope	Products with digital elements	AI systems	
Classification of regulated products	Critical, Important (Class I & II) and default category	Prohibited, High-risk, AI systems with transparency obligations, GPAI models, GPAI models with systemic risks and default category	
Value chain	Manufacturer, importer and distributor	Provider, deployer, importer and distributor	
Cybersecurity requirements	Its entirety, details in Annex I	Article 15	
Applicability of cybersecurity requirements	To all products with digital elements, regardless of classification	High-risk AI systems only	
Applicability of conformity assessment requirements	To all products with digital elements; type of conformity assessment varies by classification	High-risk AI systems only	

#### For products that are both classified as products with digital elements under CRA and as high-risk AI systems under EU AI Act:

Presumption of conformity	Products that comply with CRA Annex I essential cybersecurity requirements and have a CRA EU declaration of conformity are deemed to comply with the cybersecurity requirements under Article 15 of EU AI Act	
Conformity assessment	<ul> <li>Products without a CRA classification: follow EU AI Act conformity assessment procedures</li> <li>Critical or Important (Class I &amp; II) products: follow CRA conformity assessment for cybersecurity requirements (Art. 32 CRA), and also EU AI Act conformity assessment procedure (Art. 43 EU AI Act)</li> </ul>	
Other	<ul> <li>A single set of technical documentation shall be drawn up containing the information required by Annex VII of the CRA and by the EU AI Act (Art. 31(3) CRA)</li> <li>Cybersecurity risk assessment under CRA can be part of EU AI Act risk assessment (Art. 13(4) CRA)</li> <li>Manufacturers of the products may participate in the EU AI Act regulatory sandboxes (Art. 12(4) CRA)</li> <li>Market surveillance authorities shall be the same under the EU AI Act and the CRA (Art. 52(14) CRA)</li> </ul>	